Opendata, web and dolomites

ACQUIRE SIGNED

Assessing cardiac Contractility and Quantification of Underlying mechanisms In vitro via Response in Excitation-contraction coupling

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ACQUIRE project word cloud

Explore the words cloud of the ACQUIRE project. It provides you a very rough idea of what is the project "ACQUIRE" about.

electrical    detect    quantify    pharma    cardiomyocyte    proven    ec    service    heart    tool    quantifies    erc    cell    accommodate    acquire    incompatible    tissue    drugs    stem    3d    route    stemcardiovasc    friendliness    diseases    grant    throughput    bioassays    larger    biologically    appropriate    probes    answer    discovery    cm    tools    informative    outcome    cardiac    transient    mechanistic    abnormal    variety    apart    contraction    hipsc    flux    accurate    cardiomyocytes    software    ing    sensitive    optical    cardiotoxicity    strive    commercialisation    later    running    applicable    contractility    analysing    models    urgently    coupling    toxic    readouts    drug    calcium    commercialized    assay    paucity    minimum    function    academia    commercial    pluripotent    human    entailed    triple    myocardium    cms    fall    handling    flexibility    proof    ttm    industry    disease    modules    simultaneously    compete    intracellular    integrating   

Project "ACQUIRE" data sheet

The following table provides information about the project.

Coordinator
ACADEMISCH ZIEKENHUIS LEIDEN 

Organization address
address: ALBINUSDREEF 2
city: LEIDEN
postcode: 2333 ZA
website: www.lumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2021-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) coordinator 150˙000.00

Map

 Project objective

'Academia and industry urgently needs reliable models to study heart failure and toxic effects of drugs on the heart. While new models based on human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) are now emerging, accurate readouts of cardiomyocyte function fall short of needs. Apart from improving the models biologically, more sensitive, informative and accurate readouts are needed to detect abnormal cardiomyocyte behaviour. Several tools have proven their ability to assess electrical changes or calcium handling in hiPSC-CMs, but they are typically incompatible with 3D tissue models and moreover, there is paucity of appropriate tools to quantify the most important function of myocardium: contraction. Our ERC Advanced Grant STEMCARDIOVASC entailed the development of improved tools for cardiac functionality. One of the most important bioassays developed as an outcome of STEMCARDIOVASC was the Triple Transient Measurement (TTM) System. The TTM System quantifies electrical activity, intracellular calcium flux and contractility simultaneously and is our answer to the challenge of pharma in understanding when and how drugs or diseases affect cardiac contractility using hiPSC-CM models. In this ERC Proof of Concept project “ACQUIRE”, we strive to bring the TTM to a commercial applicable service, and later product. To reach this goal we have set out four aims to come to a Minimum Viable Product: i) increase the flexibility of the system to accommodate a larger variety of optical probes, ii) increase the throughput of the system to compete with current measurement systems, iii) increase user friendliness by integrating software modules for running and analysing measurements and iv) define a route for commercialisation. Resulting from 'ACQUIRE' the TTM System can be commercialized as a human cardiac based 3-in-1 assay for cardiotoxicity testing and a novel tool for providing mechanistic insight in the EC coupling for disease modelling and drug discovery.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ACQUIRE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ACQUIRE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ENUF (2019)

Evaluation of Novel Ultra-Fast selective III-V Epitaxy

Read More  

Diverge (2019)

Generation of ultra-deep libraries of transcriptional activators for gene therapy

Read More  

HydroLieve (2018)

A long-lasting non-migrating hydrogel for relieving chronic pain

Read More